to its Board of Directors
Osivax Appoints Dr. Michael Watson, Former President of Moderna Vaccine Division, to its Board of Directors
Company also announces upcoming presentation of clinical data for its pan-influenza vaccine candidate at World Vaccine Congress
Lyon, France – April 14, 2022
Osivax, a biopharmaceutical company developing vaccines to protect against highly mutating infectious diseases, announced today the appointment of Dr. Michael Watson to its Board of Directors. Dr. Watson brings over 20 years of experience in the research, development and commercialization of vaccines from leading biotechnology and pharmaceutical companies, including Moderna and Sanofi. He joins Osivax as it advances its lead program, OVX836, an influenza vaccine candidate designed to activate both B cell and T cell immune responses against a highly conserved internal antigen, through Phase 2 clinical studies and prepares to enter the clinic with its universal coronavirus vaccine candidate, OVX033.